Loading
CT
Cyteir Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Leonard Braden Michael, was filed 25 Mar 2024.
Cyteir Therapeutics, Inc.: what insiders have been doing
Cyteir Therapeutics, Inc. belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for Cyteir Therapeutics, Inc. The previous disclosure was published on 25 March 2024.
The full history, which starts in 2021, counts 15 purchases against 18 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
65
Thresholds
n/a
Buy Volume
€5M
15 ops. · all time
Sell Volume
€4M
18 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Net income-US$39.7M
Last declaration on 25 March 2024
Declarations65 total
170,589 shares@ US$2.9559.5% of flowCommon Stock, par value $0.001 per shareSEC:0001373604-24-000010:0
Canonical exit: 18 Jun 2024 (T+90)
113,777 shares@ US$3.0140.5% of flowCommon Stock, par value $0.001 per shareSEC:0001373604-24-000006:0
Canonical exit: 16 Jun 2024 (T+90)
2,537 shares@ US$1.200.9% of flowCommon StockSEC:0001209191-24-004438:1
6,304 shares@ US$1.693.2% of flowCommon StockSEC:0001209191-24-004438:2
4,746 shares@ US$1.695.2% of flowCommon StockSEC:0001209191-24-004439:1
2,373 shares@ US$1.692.6% of flowCommon StockSEC:0001209191-24-004439:2
12,607 shares@ US$1.698.6% of flowCommon StockSEC:0001209191-24-004438:0
3,239 shares@ US$1.685.3% of flowCommon StockSEC:0001209191-24-004439:0
14,150 shares@ US$1.69100.0% of flowCommon StockSEC:0001209191-24-003437:0
12,129 shares@ US$1.69100.0% of flowCommon StockSEC:0001209191-24-003348:0
12,828 shares@ US$1.6951.4% of flowCommon StockSEC:0001209191-24-003090:0
14,150 shares@ US$1.6913.9% of flowCommon StockSEC:0001209191-24-002992:0
2,373 shares@ US$1.692.6% of flowCommon StockSEC:0001209191-23-058610:1
2,536 shares@ US$1.200.9% of flowCommon StockSEC:0001209191-23-058609:1
6,304 shares@ US$1.694.3% of flowCommon StockSEC:0001209191-23-058609:0
1,620 shares@ US$1.682.6% of flowCommon StockSEC:0001209191-23-058610:0
21,356 shares@ US$1.6923.1% of flowCommon StockSEC:0001209191-23-056425:1
27,900 shares@ US$1.2010.0% of flowCommon StockSEC:0001209191-23-056426:1
56,737 shares@ US$1.6938.7% of flowCommon StockSEC:0001209191-23-056426:0
52,584 shares@ US$1.6884.9% of flowCommon StockSEC:0001209191-23-056425:0
100,000 shares@ US$2.753.2% of flowCommon StockSEC:0001209191-23-042977:1
1,900 shares@ US$2.76160.1% of flowCommon StockSEC:0001209191-23-042977:0
21,100 shares@ US$2.750.7% of flowCommon StockSEC:0001209191-23-042670:1
6,500 shares@ US$2.760.2% of flowCommon StockSEC:0001209191-23-042670:2
11,000 shares@ US$2.73650.8% of flowCommon StockSEC:0001209191-23-042670:0
25 of 65 declarations
About Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. It employs innovative approaches to enhance patient outcomes.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
